KRAS and neoplasm: Even though no common immunogenic epitopes are shared in these patients, a prevalent hotspot driver mutation KRAS-G12D in numerous patients can be targeted by CD8+ TILs.271 Similarly, in patients with metastatic colorectal cancer, KRAS-G12D mutant-targeted CD8+ TILs induce an efficient anti-tumor immune response against lung metastases that expressed HLA-C*08:02.387 The potential anti-tumor effect of neoantigen-reactive T cells has also been supported by retrospective investigations on the infusion of TIL products in patients with solid tumors.